Recently Analyzed

Home » has a Worldwide ranking of n/a Down n/a and ranking n/a in n/a. Using IP address in and found 0 Other Websites on this Server

The site's up time is: 439 ms

Domain Age: 3 years, 99 days (Creation Date: 2016-03-17)

Similar Webs

Check the markup (HTML, XHTML,...) of

Validate Now

  • Domain:
  • Hostname:
  • Name Servers:



  • Email Abuse:

    No Emails

  • Continent Code: OC
  • Country Code: AU
  • Country Code3: AUS
  • Country Name: Australia
  • Region: 02
  • City: Sydney
  • Postal Code: 1001
  • Latitude: -33.861198425293
  • Longitude: 151.19819641113
  • Dma Code: 0
  • Area Code: 0

Analyzed Recently

  › (2 seconds ago)

  › (1 seconds ago)

  › (2 seconds ago)

  › (1 seconds ago)

  › (5 seconds ago)

  › (6 seconds ago)

  › (1 seconds ago)

  › (1 seconds ago)

  › (3 seconds ago)

  › (0 seconds ago)

  › (0 seconds ago)

  › (7 seconds ago)

  › (1 seconds ago)

  › (1 seconds ago)

  › (2 seconds ago)

  › (3 seconds ago)

  › (1 seconds ago)

  › (2 seconds ago)

  › (1 seconds ago)

  › (4 seconds ago)

Keywords Suggestions

  › Mdm2 inhibitors
  › Mdm2 inhibitors palbociclib
  › Mdm2 inhibitor sarcoma therapy
  › Mdm2 inhibitor moa
  › Mdm2 inhibitor drugs
  › Mdm2 inhibitor mpn
  › Mdm2 inhibitor 2018
  › Mdm2 inhibitor mskcc
  › Mdm2 inhibitor ctdna
  › Mdm2 inhibitor amg-232
  › Mdm2 inhibitor neutlin
  › Mdm2 inhibitor in acc

MetaTags & Keyword Analysis

Websites Listing Results search for results as listed below with the link list and email address for this website

Mdm2 - Wikipedia

Mouse double minute 2 homolog (MDM2) also known as E3 ubiquitin-protein ligase Mdm2 is a protein that in humans is encoded by the MDM2 gene. Mdm2 is an important negative regulator of the p53 tumor suppressor. Mdm2 protein functions both as an E3 ubiquitin ligase that recognizes the N-terminal trans-activation domain (TAD) of the p53 tumor suppressor and as an inhibitor of p53 transcriptional

Link: (Actived: Thursday Jun 20, 2019)

Clinical Overview of MDM2/X-Targeted Therapies

The three major biomarkers that have been used to evaluate therapeutic responses to MDM2/X inhibitors are p53 status, MDM2, and MDMX levels. Interestingly, the over expression of MDM2, MDMX, or mutation of p53 are often mutually exclusive.

Link: (Actived: Saturday Jan 15, 2011)

MDM2/X inhibitors under clinical evaluation: perspectives ...

Resistance to treatment occurs through the development of P53 mutant-clones and as result of other molecular defects and/or altered expression of molecules, such as MDMX, that can confer resistance to MDM2 inhibitors. Hoffman-Luca and colleagues have recently addressed the mechanisms of acquired resistance focusing on the MDM2 inhibitor SAR405838.

Link: (Actived: Tuesday Jun 18, 2019)

Small-Molecule Inhibitors of the MDM2–p53 Protein–Protein ...

Design of small-molecule inhibitors (MDM2 inhibitors) to block the MDM2–p53 protein–protein interaction has been pursued as a new cancer therapeutic strategy. In recent years, potent, selective, and efficacious MDM2 inhibitors have been successfully obtained and seven such compounds have been advanced into early phase clinical trials for the treatment of human cancers.

Link: (Actived: Sunday Apr 7, 2019)

Clinical Trials Using MDM2 Inhibitor AMG-232 - National ...

MDM2 inhibitor AMG-232 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving MDM2 inhibitor AMG-232 and radiation therapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed.

Link: (Actived: Thursday Jun 20, 2019)

Mdm2 | Mdm signaling

MX69 is a MDM2/XIAP inhibitor that binds to MDM2 RING protein with binding Kd values of 2.34 μM. It is used for cancer treatment. S8606: HDM201. HDM201 is a novel, highly potent and selective inhibitor of the p53-Mdm2 interaction with affinity constant for Mdm2 in the picomolar range and a selectivity ratio greater than 10000-fold vs Mdm4.

Link: (Actived: Friday Jun 14, 2019)

MDM2 inhibitors for cancer therapy - ScienceDirect

Inhibitors of the p53–MDM2 interaction activate p53 by direct interference with MDM2 binding and thus can fully compensate for any defects in the upstream components of the p53 pathway. However, defective downstream p53 signaling might substantially decrease their effectiveness.

Link: (Actived: Wednesday May 29, 2019)

P53 Mdm2 Inhibitors - PubMed Central (PMC)

3. NUTLIN. Hoffmann La Roche set out via high throughput screening to find potent and selective p53/MDM2 inhibitors. One class of compounds was a series of cis-imidazoline analogs termed Nutlins (Scheme 1).These compounds displaced p53 from MDM2 with an IC50 in the 100 to 300 nM range.

Link: (Actived: Thursday Feb 17, 2005)

MDM2 Inhibitors | SCBT - Santa Cruz Biotechnology

MDM2 Inhibitors p53 is the most commonly mutated gene in human cancer identified to date. Biochemicals that inhibit MDM2 have many applications in biochemical and physiological research.

Link: (Actived: Thursday Jun 6, 2019)

MDM2 inhibitors could be promising new treatment for uveitis

The research team studied the effects of MDM2 in mice by using an agent that blocks MDM2. Inflammation was nearly abolished with systemic and ocular delivery of the MDM2 inhibitor.

Link: (Actived: Wednesday Oct 31, 2018)

Mdm2 | Mdm signaling inhibitors | Mdm2 inhibitor

MDM2 Inhibitor is a cell-permeable boranyl-chalcone exhibiting strong binding to MDM2 and irreversibly disrupts the MDM2/p53 protein complex. A10657 SALE: Nutlin-3: Mdm2 antagonist : MDM2 antagonist nutlin-3 is a potent inducer of apoptosis. Product Citations (4)

Link: (Actived: Wednesday Jun 12, 2019)